notoginsenoside-r1 and Diabetic-Angiopathies

notoginsenoside-r1 has been researched along with Diabetic-Angiopathies* in 1 studies

Other Studies

1 other study(ies) available for notoginsenoside-r1 and Diabetic-Angiopathies

ArticleYear
Notoginsenoside R1 Facilitated Wound Healing in High-Fat Diet/Streptozotocin-Induced Diabetic Rats.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Diabetic ulcers bring about high morbidity and mortality in patients and cause a great economic burden to society as a whole. Since existing treatments cannot fulfil patient requirements, it is urgent to find effective therapies. In this study, the wound healing effect of topical notoginsenoside R1 (NR1) treatment on diabetic full-thickness wounds in type II diabetes mellitus (T2DM) was induced by the combination of a high-fat diet and streptozotocin (STZ) injection. NR1 significantly increased the wound closure rate, enhanced extracellular matrix (ECM) secretion, promoted collagen growth, increased platelet endothelial cell adhesion molecule-1 (CD31) expression, and decreased cleaved caspase-3 expression. RNA-Seq analysis identified ECM remodeling and inflammation as critical biological processes and Timp1 and Mmp3 as important targets in NR1-mediated wound healing. Further experiments showed that NR1-treated wounds demonstrated higher expression of tissue inhibitor of metalloproteinase 1 (TIMP1) and transforming growth factor-

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diet, High-Fat; Ginsenosides; Humans; Male; Panax; Rats; Rats, Sprague-Dawley; Streptozocin; Ulcer; Wound Healing

2022